Paradigm Biopharmaceuticals (ASX:PAR) has reached an important scientific milestone with the peer-reviewed publication of results from its Phase 2 biomarker study investigating injectable pentosan polysulfate sodium (iPPS) in patients with moderate to severe knee osteoarthritis. …
Peer-reviewed validation strengthens Paradigm’s osteoarthritis program
January 28, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News -
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL presses ahead with transformation as earnings slip and leadership changes
February 11, 2026 - - Latest News -
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 - - Latest News -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News